RxDoctor Payments Data

Niki Hodges, APRN

Family Medicine · Santa Fe, TXNPI 1417201732

Payments from drug & device makers

$840in general payments, 2019–2025

Across 29 payments — averaging $28.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merz North America, Inc.$222
  • AbbVie$217
  • Axonics, Inc.$117
  • Lilly USA, LLC$67
  • Takeda Pharmaceuticals U.S.A., Inc.$53
  • AstraZeneca$36
  • plus $129 from 6 others

What the payments were for

  • Food & beverage$840100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$840 in reported general payments places this provider in the 55th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$176,644
Medicare patients
566
Services billed
9,838

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide71$87,648
FarxigaDapagliflozin Propanediol60$62,206
OzempicSemaglutide41$53,044
EliquisApixaban31$21,819
JardianceEmpagliflozin13$17,893
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$11,471
Soliqua 100-33Insulin Glargine/Lixisenatide11$8,949
Duloxetine Hcl62$2,819
Rosuvastatin Calcium149$2,193
Gabapentin90$2,193
Levothyroxine Sodium246$2,083
Atorvastatin Calcium202$2,066
SynthroidLevothyroxine Sodium19$1,981
Montelukast Sodium158$1,915
Valsartan88$1,772

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$67$87,64871 claims
AstraZenecaFarxiga$36$62,20660 claims
Novo NordiskOzempic$16$53,04441 claims
AbbVieSynthroid$217$1,98119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Santa Fe

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →